Serum samples were collected pre- and post-booster vaccination with Comirnaty in 626 participants (aged ≥ 50 years) who had received two Comirnaty doses < 30 days apart, two Comirnaty doses ≥ 30 days apart or two Vaxzevria doses ≥ 30 days apart. Irrespective of primary vaccine type or schedule, spike antibody GMTs peaked 2–4 weeks after second dose, fell significantly ≤ 38 weeks later and rose above primary immunisation GMTs 2–4 weeks post-booster. Higher post-booster responses were observed with a longer interval between primary immunisation and boosting.
All Keywords
【저자키워드】 COVID-19, Immunity, antibody, Spike protein, Pfizer, COVID-Vaccine, AstraZeneca, Comirnaty, Vaxzevria, 【초록키워드】 Vaccine, vaccination, response, second dose, participant, serum sample, collected, peaked, GMT, 【제목키워드】 response, United Kingdom, London, Booster vaccine,
【저자키워드】 COVID-19, Immunity, antibody, Spike protein, Pfizer, COVID-Vaccine, AstraZeneca, Comirnaty, Vaxzevria, 【초록키워드】 Vaccine, vaccination, response, second dose, participant, serum sample, collected, peaked, GMT, 【제목키워드】 response, United Kingdom, London, Booster vaccine,